Paul P. Dobesh, PharmD, FCCP, BCPS
Associate Professor of Pharmacy Practice
College of Pharmacy
University of Nebraska Medical Center
Omaha, Nebraska

Ann Wittkowsky, PharmD, CACP, FASHP, FCCP
Clinical Professor of Pharmacy
University of Washington
School of Pharmacy
Director of Anticoagulation Services
University of Washington Medical Center
Seattle, Washington

After completing this activity, participants should be able to:

• Describe the pathophysiology of thrombosis and hypercoagulability of cancer
• Apply guideline-directed risk stratification and venous thromboembolism (VTE) prophylaxis in patients with cancer
• Outline the safety and efficacy of current and investigational medications for VTE prophylaxis in patients with cancer
• Implement or adhere to discharge protocols that ensure appropriate duration of VTE prophylaxis in cancer patients transitioning from inpatient to outpatient care

All educational activities are accessible via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. Windows Media Player or compatible alternative, sound card, and speakers are required for streamed audio. The latest version of the Adobe Flash Player is suggested (please download here) for video programs. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

This activity is approved for 1 contact hour (0.1 CEU) of continuing pharmacy education (UAN 276-000-11-010-H01-P).

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact Assistant Director, Accreditation Services, NACCME, in writing at 300 Rike Drive, Suite A, Millstone Township, NJ 08535. The Assistant Director, Accreditation Services will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation Services, NACCME, may be made for a second level of review.

This educational activity is a knowledge-based activity.

Independent Clinical Reviewer: Wendy Cantrell, PharmD, BCPS, BCNSP, CACP, Cardiology/Anticoagulation Specialist, University Medical Center of Southern Nevada, Assistant Professor, University of Southern Nevada College of Pharmacy, Las Vegas, Nevada

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Dobesh, Dr. Wittkowsky, and Dr. Cantrell have disclosed no relevant financial relationships with any commercial interests.

Ms. Ciszeski, Ms. Johnson, Mr. Kearney, Mr. Robbin, and Mr. Savage have disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty has disclosed that no off-label/unapproved use(s) of drugs and/or devices will be discussed.